


Polycystic Ovary Syndrome (PCOS) Treatment Market to reach over USD 5.26 billion by the year 2030-InsightAce Analytic

Global polycystic ovary syndrome (PCOS) treatment market is estimated to reach over USD 5.26 billion by 2030, exhibiting a CAGR of 5.13% during the forecast

NEW JERSEY, NJ, USA, November 23, 2022 /EINPresswire.com/ -- InsightAce Analytics Pvt. Ltd. announces the release of a market assessment report on the "[Global Polycystic Ovary Syndrome \(PCOS\) Treatment Market](#) (By Tdrug class (Oral Contraceptives, Insulin Sensitizing Agents, Antidepressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs and diuretics) and Distribution Channel (Hospital Pharmacies, Drug Stores/OTC, E-Commerce And Clinics))- Market Outlook and Industry Analysis 2030"



Polycystic Ovary Syndrome (PCOS) Treatment market Info



Major Players in the Polycystic Ovary Syndrome (PCOS) Treatment Market: Novartis AG, Sanofi, Teva Pharmaceutical Industries Limited, Merck & Co., AstraZeneca, Bayer AG, Abbott, Pfizer”

Insightace Analytic

The global [polycystic ovary syndrome \(PCOS\) treatment](#) market is estimated to reach over USD 5.26 billion by 2030, exhibiting a CAGR of 5.13% during the forecast period.

Request For Sample:


<https://www.insightaceanalytic.com/request-sample/1455>

A hormonal condition known as PCOS, or polycystic ovarian syndrome, is prevalent in women of childbearing age. PCOS can result in irregular or extended menstrual

cycles or high amounts of male hormones. There is currently no cure for PCOS. However, several drugs are used to manage the condition's symptoms and the menstrual cycle. An increase in PCOS prevalence, an increase in patient population awareness, and an increase in the adoption

of combination therapy drives the growth of the polycystic ovarian syndrome treatment market. Additionally, the market growth is influenced by the ease of access to polycystic ovary syndrome (PCOS) treatment, increased demand for PCOS drugs, and technological developments for PCOS screening. However, the absence of authorized treatments and the unclear pathophysiology and etiology of PCOS are expected to restrain market expansion.

Furthermore, during the anticipated time, the developing economies' untapped potential offers profitable chances for expanding the polycystic ovary syndrome (PCOS) treatment market. The demand for polycystic ovary syndrome (PCOS) treatment is anticipated to increase as PCOS prevalence rises.



Prominent Players in the Polycystic Ovary Syndrome (PCOS) Treatment Market:

- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Limited
- Merck & Co., Inc. (Merck group)
- AstraZeneca plc.
- Bayer AG
- Abbott
- Pfizer, Inc
- Bristol-Myer Squibb Company
- Ferring Pharmaceuticals, Inc.
- Johnson and Johnson
- Mylan N.V.
- Allergan plc.
- GlaxoSmithKline
- Lupin Pharmaceuticals
- AbbVie
- Takeda
- BIOCAD Global
- Blair Laboratories Inc
- Agile Therapeutics

Market Dynamics:

Drivers-

The main element fueling this market's growth is the sharp increase in polycystic ovarian

syndrome (PCOS) instances around the globe. The market's overall expansion is also anticipated to be accelerated by additional causes, such as the rising prevalence of diabetes and obesity among women, the rise in hormonal diseases, socioeconomic factors, changes in sedentary behavior, and increased consumption of unhealthful diets. Additionally, it is anticipated that the growing healthcare industry, the use of combination medications, and greater patient adoption will all contribute to market expansion. Furthermore, the growing awareness of chronic illnesses and hospital-acquired infections among patients and physicians slows the market's growth during the anticipated timeframe.

Challenges:

There are several adverse effects associated with polycystic ovary syndrome medications. Drug-related side effects include increased insulin resistance, altered glucose tolerance, weight gain, and thromboembolic events are predicted to hinder market expansion. The market for treating polycystic ovarian syndrome (PCOS) is expected to have challenges during the forecast period due to a shortage of FDA-approved drugs and approved treatments. Additionally, the lack of a targeted treatment for this condition and the unidentified etiology and pathophysiology of polycystic ovarian syndrome would restrain the market's overall expansion.

Regional Trends:

The Asia Pacific polycystic ovary syndrome (PCOS) treatment market is expected to register a major market share in revenue and is projected to grow at a high CAGR shortly. The market will grow as more people become aware of the condition's treatment options and solutions for treating polycystic ovarian syndrome gain popularity. The expansion of the market is also aided by the growth of the R&D sector, the growth of the target market, the expansion of healthcare reforms, and technical advancements in the healthcare sector. Additionally, North America is anticipated to expand at a significant rate over the course of the forecast period. Factors like a sizable population base and high disposable incomes are anticipated to fuel the growth of the region's polycystic ovarian syndrome treatment market. Major manufacturers have also increased their focus on expanding their geographic presence to seize high-growth opportunities in the market.

Enquiry Before Buying: <https://www.insightaceanalytic.com/enquiry-before-buying/1455>

Recent Developments:

- In January 2020, Elagolix, a substance being studied by Abbvie in a clinical trial for its safety and effectiveness in treating polycystic ovarian syndrome in female patients, Elagolix's safety and effectiveness in treating women with polycystic ovarian syndrome currently being examined in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study being carried out by the company (PCOS).
- In January 2020, a new five-year multi-target partnership between Evotec SE and Bayer AG and Celmatix Inc. was underway to develop a number of clinical candidates for the management of polycystic ovarian syndrome, which is anticipated to dominate the market over the forecast period.

Segmentation of Polycystic Ovary Syndrome (PCOS) Treatment Market-

By Drug Class-

- Oral Contraceptives
- Insulin Sensitizing Agents
- Antidepressants
- Ornithine Decarboxylase Inhibitors
- Aromatase Inhibitors & SERMs
- Diuretics

By Distribution channel-

- Hospital Pharmacies
- Drug Stores/OTC
- e-Commerce
- Clinics

By Region-

North America-

- The US
- Canada
- Mexico

Europe-

- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe

Asia-Pacific-

- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific

Latin America-

- Brazil
- Argentina
- Rest of Latin America

Middle East & Africa-

- GCC Countries
- South Africa
- Rest of Middle East and Africa

Priyanka Tilekar
Insightace Analytic Pvt. Ltd.
+1 551-226-6109
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/602760046>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.